Italia markets closed

Kinarus Therapeutics Holding AG (0QNS.L)

LSE - LSE Prezzo differito. Valuta in CHF.
Aggiungi a watchlist
0,0250+0,0250 (+84,00%)
Alla chiusura: 05:01PM BST
Schermo intero
Chiusura precedente0,0000
Aperto0,0250
Denaro0,0000 x N/D
Lettera0,0000 x N/D
Min-Max giorno0,0250 - 0,0250
Intervallo di 52 settimane0,0250 - 0,0250
Volume6
Media VolumeN/D
Capitalizzazione52.797
Beta (5 anni mensile)N/D
Rapporto PE (ttm)N/D
EPS (ttm)-0,0010
Prossima data utiliN/D
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Kinarus Therapeutics Reports H1 2022 Financial Results and Provides Corporate Update

    Interim data from Phase 2 KINETIC clinical trial of KIN001 to treat hospitalized COVID-19 patients expected in Q3 2022First patient dosed with in Phase 2 KINFAST clinical trial with ambulatory COVID-19 mild-patientsSigned a CHF 20 million financing with Yorkville Advisors Fully financed until Q1 2023 Basel, Switzerland, August 31, 2022 – Kinarus Therapeutics Holding AG (SIX: KNRS), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory and ophthalmic

  • GlobeNewswire

    Kinarus Therapeutics initiates KIN001 Phase II KINFAST clinical trial in COVID-19 outpatients

    KINFAST to evaluate ability of KIN001 to reduce severity and duration of symptoms in ambulatory COVID-19 patientsInterim data from ongoing Phase 2 KINETIC trial in hospitalized Covid-19 patients expected in late Q3 2022 Basel, Switzerland, 29 August 2022 -- Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus”), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory, and ophthalmic diseases today announced that the first patient has been dosed in th

  • GlobeNewswire

    Kinarus Therapeutics to hold webinar on a new approach to treating COVID-19

    KIN001 has synergistic antiviral, anti-inflammatory activity, and anti-fibrotic mechanismsPhase 2 trials of KIN001 in hospitalized and ambulatory COVID-19 patients ongoingInterim data from Phase 2 study in hospitalized COVID-19 patients expected end of Q3Webinar on Aug 24 starts at 2:00 pm CET (8:00 am ET) Basel, Switzerland, 22 August 2022 -- Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus”), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respirat